KISSPEPTIN AN EVIDENCE-BASED RESEARCH REVIEW
PART 1
Research status: Investigational research peptide
Evidence base: Preclinical and human research
Human research: Published experimental and clinical studies
Established therapeutic indication: Not established
INTRODUCTION
Kisspeptin is a naturally occurring peptide system that plays an important role in reproductive endocrine signalling.
Research has established a relationship between kisspeptin signalling, gonadotropin-releasing hormone neurons and downstream reproductive hormone regulation.
Unlike many experimental peptides, kisspeptin has been investigated in a substantial body of human research.
Studies have examined its physiological activity in healthy participants as well as its experimental use within specialist reproductive research.
However, evidence of biological activity and participation in human research should not be interpreted as establishing kisspeptin as an approved or generally established therapeutic treatment.
This article reviews the biological role of kisspeptin, human and preclinical research, mechanisms under investigation and important limitations within the current evidence base.
WHAT IS KISSPEPTIN?
Kisspeptins are peptide products derived from the KISS1 gene.
Several biologically active forms have been described, including kisspeptin-10 and kisspeptin-54.
These peptides interact with the kisspeptin receptor, generally referred to as KISS1R and historically known as GPR54.
The kisspeptin and KISS1R signalling system has become an important area of neuroendocrine research because of its relationship with the hypothalamic-pituitary-gonadal axis.
Research involving both animals and humans has demonstrated that this signalling system plays an important role in normal reproductive physiology.
However, involvement in a biological pathway does not by itself establish a therapeutic application.
KISSPEPTIN AND KISS1R SIGNALLING
Kisspeptin binds to KISS1R, a G-protein-coupled receptor.
KISS1R signalling influences gonadotropin-releasing hormone neurons within the hypothalamus.
Gonadotropin-releasing hormone subsequently contributes to the regulation of luteinising hormone and follicle-stimulating hormone.
These hormones form part of the wider endocrine system involved in reproductive physiology.
This pathway provides researchers with a biological mechanism through which kisspeptin signalling can be investigated.
Understanding this mechanism does not independently establish clinical effectiveness.
REPRODUCTIVE ENDOCRINOLOGY RESEARCH
Reproductive endocrinology represents one of the most extensively investigated areas of kisspeptin research.
Studies have examined relationships between kisspeptin signalling and:
Gonadotropin-releasing hormone activity
Luteinising hormone secretion
Follicle-stimulating hormone secretion
Pubertal development
Reproductive hormone regulation
Ovarian physiology
Endocrine feedback mechanisms
Human genetic evidence has also contributed to understanding the biological importance of the kisspeptin system.
Changes affecting KISS1 or KISS1R signalling have been associated with altered reproductive development.
This provides additional evidence that the pathway is an important component of human reproductive physiology.
HUMAN RESEARCH
Kisspeptin has been investigated directly in human participants.
Controlled experimental studies have demonstrated measurable effects involving reproductive endocrine signalling.
Research involving kisspeptin-10 has examined luteinising hormone and follicle-stimulating hormone responses in human participants.
Other studies have investigated kisspeptin-54.
The human literature therefore provides considerably more direct evidence of biological activity than exists for many experimental research peptides.
Importantly, this does not mean that every proposed application of kisspeptin has been clinically established.
The strength of evidence depends on the specific research question, peptide form, study population and outcome being investigated.
KISSPEPTIN-10 AND KISSPEPTIN-54
The term kisspeptin can refer to several related peptide forms.
Two frequently investigated forms are kisspeptin-10 and kisspeptin-54.
Both interact with KISS1R, although their pharmacokinetic characteristics and experimental conditions can differ.
Researchers should therefore identify which form of kisspeptin was investigated when interpreting individual studies.
Evidence obtained using one form should not automatically be assumed to describe every kisspeptin preparation.
HUMAN ENDOCRINE RESEARCH
Human studies have demonstrated that experimental kisspeptin exposure can influence measurable reproductive hormone responses.
Research has reported changes involving luteinising hormone and, under certain experimental conditions, follicle-stimulating hormone and other downstream endocrine markers.
These findings provide direct evidence that kisspeptin can influence the human hypothalamic-pituitary-gonadal axis under experimental conditions.
However, a measurable hormonal response represents evidence of biological and pharmacodynamic activity.
It should not automatically be interpreted as evidence of a clinical benefit.
OOCYTE MATURATION RESEARCH
One developed area of human kisspeptin research involves specialist reproductive medicine.
Published clinical research has investigated kisspeptin-54 in women undergoing in vitro fertilisation treatment.
A 2014 study involving 53 women investigated whether kisspeptin-54 could trigger oocyte maturation under controlled research conditions.
Subsequent research investigated kisspeptin-54 in women considered at increased risk of ovarian hyperstimulation syndrome.
These studies represent meaningful human clinical research rather than purely laboratory or animal evidence.
However, findings from specialist clinical research environments should be interpreted within the context of the specific protocols, formulations and participant populations investigated.
PART 2
PUBERTY AND DEVELOPMENTAL RESEARCH
The kisspeptin signalling system has also been investigated extensively in relation to pubertal development.
Animal models and human genetic research have demonstrated that disruption of kisspeptin signalling can affect reproductive development.
This evidence has helped establish the KISS1 and KISS1R pathway as an important regulator within reproductive neuroendocrinology.
Researchers continue to investigate how changes in kisspeptin signalling relate to the initiation and regulation of puberty.
NEUROENDOCRINE RESEARCH
Kisspeptin is also studied as a neuroendocrine signalling molecule.
The interaction between kisspeptin neurons, gonadotropin-releasing hormone neurons and circulating reproductive hormones forms part of a complex biological feedback system.
Experimental research has examined how this system responds to physiological and hormonal changes.
This illustrates why kisspeptin research extends beyond measuring individual hormone concentrations.
Researchers are investigating a wider signalling network involved in coordinating reproductive endocrine physiology.
OTHER AREAS UNDER INVESTIGATION
The scientific literature has explored additional biological functions associated with kisspeptin signalling.
Research areas include:
Neuroendocrine signalling
Pregnancy biology
Placental biology
Metabolic signalling
Behavioural neuroscience
Reproductive disorders
Assisted reproductive research
Some areas have substantially more evidence than others.
The existence of exploratory research should therefore not be interpreted as establishing therapeutic effectiveness in each area.
BIOLOGICAL ACTIVITY VERSUS CLINICAL EFFECTIVENESS
This distinction is particularly important when interpreting kisspeptin research.
Human studies demonstrate that kisspeptin can produce measurable biological responses.
These include changes in reproductive endocrine signalling and, within specialist research settings, responses relevant to oocyte maturation.
This represents stronger evidence than laboratory observations alone.
However, biological activity does not automatically establish:
A generally established therapeutic indication
Long-term clinical effectiveness
Long-term safety across different populations
Effectiveness for every proposed application
Equivalence between different kisspeptin forms or preparations
Each proposed application requires evidence appropriate to that particular research question.
HUMAN VERSUS ANIMAL EVIDENCE
Kisspeptin research includes both preclinical and human evidence.
LABORATORY RESEARCH
Cellular and molecular studies have helped characterise KISS1R signalling and associated biological pathways.
These studies are useful for investigating mechanisms but cannot independently establish clinical effectiveness.
ANIMAL RESEARCH
Animal models have contributed substantially to understanding reproductive development, gonadotropin-releasing hormone signalling and endocrine physiology.
Animal findings cannot automatically be extrapolated to humans.
HUMAN PHYSIOLOGICAL RESEARCH
Controlled human studies have demonstrated measurable reproductive endocrine responses.
This provides direct evidence of biological activity in humans under the conditions investigated.
HUMAN CLINICAL RESEARCH
Kisspeptin-54 has been investigated within specialist reproductive research, including studies involving oocyte maturation.
These findings apply to the particular peptide preparation, population and research conditions studied.
CURRENT RESEARCH LIMITATIONS
DIFFERENT PEPTIDE FORMS
Kisspeptin-10 and kisspeptin-54 have different experimental and pharmacokinetic characteristics.
Evidence involving one form should not automatically be attributed to another.
SPECIALIST STUDY POPULATIONS
Some human research has involved carefully selected populations within specialist clinical research environments.
Results should be interpreted within those study populations.
BIOLOGICAL MARKERS VERSUS OUTCOMES
Changes in luteinising hormone, follicle-stimulating hormone or other endocrine markers demonstrate biological activity but do not independently establish broader clinical outcomes.
APPLICATION-SPECIFIC EVIDENCE
Evidence supporting one experimental application cannot automatically support unrelated proposed applications.
LONG-TERM EVIDENCE
Long-term evidence across broad populations remains more limited than short-duration physiological research.
PRODUCT-SPECIFIC EVIDENCE
Research involving characterised materials within controlled studies should not automatically be attributed to other kisspeptin preparations.
CURRENT RESEARCH ASSESSMENT
Kisspeptin has a well-characterised biological role within reproductive neuroendocrine signalling.
Unlike research compounds supported primarily by laboratory and animal evidence, kisspeptin has also undergone meaningful investigation in humans.
Published studies demonstrate measurable effects on reproductive endocrine signalling, and clinical research has investigated kisspeptin-54 within specialist reproductive settings.
The evidence therefore supports describing kisspeptin as an investigational peptide within reproductive and neuroendocrine research.
However, the existence of human studies does not establish unrestricted therapeutic effectiveness or justify extrapolation beyond the specific conditions investigated.
EVIDENCE SUMMARY
Laboratory research: Substantial
Animal research: Substantial
Human physiological research: Published evidence
Human reproductive research: Published evidence
KISS1 and KISS1R biological role: Well characterised
Long-term evidence across broad populations: Limited
Evidence for all proposed applications: Not established
General established therapeutic indication: Not established
CONCLUSION
Kisspeptin represents an important area of reproductive and neuroendocrine research.
Evidence from molecular studies, animal models, human genetics and controlled human experiments supports an important physiological relationship between kisspeptin and KISS1R signalling and regulation of the reproductive endocrine system.
Human studies have demonstrated measurable effects on reproductive endocrine signalling, while specialist clinical research has investigated kisspeptin-54 within reproductive medicine.
This gives kisspeptin a more developed human evidence base than many experimental peptides.
Nevertheless, the evidence must be interpreted according to the particular kisspeptin form, study population, experimental design and outcome being investigated.
Evidence demonstrating biological activity should not be expanded into claims concerning applications that have not themselves been adequately studied.
Kisspeptin is therefore best described as an investigational peptide with substantial biological research and meaningful human experimental evidence, while many potential applications remain under investigation.
REFERENCES
Clarke SA, Dhillo WS. Kisspeptin across the human lifespan: evidence from animal studies and beyond. Journal of Endocrinology. 2016. PMID 27340201.
Jayasena CN, et al. Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization. Journal of Clinical Investigation. 2014. PMID 25036713.
Abbara A, et al. Efficacy of Kisspeptin-54 to Trigger Oocyte Maturation in Women at High Risk of Ovarian Hyperstimulation Syndrome During In Vitro Fertilization Therapy. Journal of Clinical Endocrinology and Metabolism. 2015. PMID 26192876.
Sharma B, Koysombat K, Comninos AN, Dhillo WS, Abbara A. Use of kisspeptin to trigger oocyte maturation during in vitro fertilisation treatment. Frontiers in Endocrinology. 2022. PMID 36147569.
Skorupskaite K, George JT, Anderson RA. The kisspeptin-GnRH pathway in human reproductive health and disease. Human Reproduction Update. 2014. PMID 24615662.
RESEARCH DISCLAIMER
This article is provided for educational and scientific research purposes only.
Kisspeptin is discussed in the context of published scientific research.
The existence of laboratory, animal or human studies should not be interpreted as establishing a general therapeutic indication or as demonstrating that any research product is suitable for human use.
Research findings should be interpreted according to peptide identity, study design, participant population, methodology and level of evidence.
Products supplied by Evolve Peptides are intended strictly for laboratory and scientific research purposes and are not intended for human or veterinary use.
